Severe Legionnaires' Disease Successfully Treated with Levofloxacin and Azithromycin
Abstract
Fluoroquinolones are the most active drugs against Legionella in intracellular and animal models, achieving high intracellular levels and low MICs. In patients with human immunodeficiency virus infection, Legionnaires' disease (LD) has a more severe clinical presentation and worse evolution, with a mortality rate of up to 20%. This chapter presents a case of a severely inmunosuppressed woman with LD in whom treatment failed with levofloxacin and who recovered after the addition of azithromycin. The intracellular location of the pathogen is relevant to the efficacy of the antibiotic. At present, new macrolides such as clarithromycin and azithromycin and fluoroquinolones are the most active drugs in the treatment of Legionella pneumonia. Even though the advances in rapid specific diagnosis and the greater efficacy of the new macrolides and quinolones have led to a better prognosis of Legionella pneumonia, mortality continues to be very high in immunosuppressed patients. Thus, randomized trials comparing the efficacy of combination therapies with new macrolides and quinolones versus monotherapy should be performed to evaluate their real impact in reducing morbidity and mortality of Legionella pneumonia with bad prognostic factors.
How strong is the evidence?
Evidence Hub reads this as a randomized trial, done in people. Its evidence level is 2 of 5 (High · randomized trial). Randomized trials of a reasonable size are the strongest single-study design.
Read the paper
Related studies
- Severe clinical outcomes of COVID-19 associated with proton pump inhibitors: a nationwide cohort study with propensity score matching
- Thiophenes—Naturally Occurring Plant Metabolites: Biological Activities and In Silico Evaluation of Their Potential as Cathepsin D Inhibitors
- Inhalable Mannosylated Rifampicin–Curcumin Co-Loaded Nanomicelles with Enhanced In Vitro Antimicrobial Efficacy for an Optimized Pulmonary Tuberculosis Therapy
- Association between cord blood 25-hydroxyvitamin D concentrations and respiratory tract infections in the first 6 months of age in a Korean population: a birth cohort study (COCOA)
- GC-MS Analysis and Biomedical Therapy of Oil from n-Hexane Fraction of Scutellaria edelbergii Rech. f.: In Vitro, In Vivo, and In Silico Approach
- Novel Pharmacokinetic/Pharmacodynamic Parameters Quantify the Exposure–Effect Relationship of Levofloxacin against Fluoroquinolone-Resistant Escherichia coli
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.